G1 Therapeutics (GTHX) Upgraded to “Hold” by BidaskClub

BidaskClub upgraded shares of G1 Therapeutics (NASDAQ:GTHX) from a sell rating to a hold rating in a report published on Wednesday morning.

Several other research analysts also recently commented on GTHX. BTIG Research started coverage on G1 Therapeutics in a research report on Tuesday, December 19th. They issued a buy rating and a $38.00 price target on the stock. Zacks Investment Research cut G1 Therapeutics from a hold rating to a sell rating in a research report on Wednesday, October 11th. Finally, Cowen restated a buy rating on shares of G1 Therapeutics in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $31.40.

Shares of G1 Therapeutics (GTHX) traded down $0.40 during midday trading on Wednesday, reaching $20.00. The company’s stock had a trading volume of 91,300 shares, compared to its average volume of 109,500. G1 Therapeutics has a 52 week low of $12.04 and a 52 week high of $28.67.

In other G1 Therapeutics news, major shareholder Medimmune Ventures, Inc. sold 133,906 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $19.75, for a total value of $2,644,643.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Fredric N. Eshelman purchased 250,000 shares of the stock in a transaction on Monday, November 13th. The stock was bought at an average price of $19.73 per share, for a total transaction of $4,932,500.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 541,406 shares of company stock worth $10,746,719.

A number of large investors have recently made changes to their positions in the business. Alps Advisors Inc. grew its position in G1 Therapeutics by 9.1% in the third quarter. Alps Advisors Inc. now owns 27,766 shares of the company’s stock valued at $691,000 after acquiring an additional 2,317 shares during the period. Chartwell Investment Partners LLC grew its position in G1 Therapeutics by 5.0% in the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after acquiring an additional 4,388 shares during the period. American International Group Inc. bought a new stake in G1 Therapeutics in the third quarter valued at $130,000. California State Teachers Retirement System bought a new stake in G1 Therapeutics in the third quarter valued at $319,000. Finally, Schwab Charles Investment Management Inc. bought a new stake in G1 Therapeutics in the third quarter valued at $364,000. Hedge funds and other institutional investors own 43.25% of the company’s stock.

TRADEMARK VIOLATION WARNING: “G1 Therapeutics (GTHX) Upgraded to “Hold” by BidaskClub” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://transcriptdaily.com/2018/01/05/g1-therapeutics-gthx-upgraded-to-hold-by-bidaskclub.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply